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Abstract
Chronic hypertension during aging is a serious threat to the cerebral vasculature. The larger brain arteries can react to hypertension with
an abnormal wall thickening, a loss of elasticity and a narrowed lumen. However, little is known about the hypertension-induced alterations
of cerebral capillaries. The present study describes ultrastructural alterations of the cerebrocortical capillary wall, such as thickening and
collagen accumulation in the basement membrane of aging spontaneously hypertensive stroke-prone rats. The ratio of cortical capillaries
with such vascular pathology occurred significantly more frequently in hypertensive animals.
Nimodipine and nifedipine are potential drugs to decrease blood pressure in hypertension but their beneficial effects in experimental
studies reach beyond the control of blood pressure. Nimodipine and nifedipine can alleviate ischemia-related symptoms and improve
cognition. These drugs differ in that nifedipine, but not nimodipine reduces blood pressure at the here-used concentration while both drugs
can penetrate the blood-brain barrier. Here we show that chronic treatment of aging hypertensive stroke-prone rats with nimodipine or
nifedipine could preserve microvascular integrity in the cerebral cortex. © 2001 Elsevier Science Inc. All rights reserved.
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1. Introduction
Chronic hypertension has a profoundly detrimental effect
on cerebral circulation and brain function. For experimental
approaches to study hypertension, the spontaneously hyper-
tensive stroke prone rat strain (SHR-SP) proved to be an apt
animal model to investigate the consequences of prevailing
hypertension on behavior, neuronal integrity and cerebro-
vascular parameters. Preliminary studies demonstrated that
chronic hypertension in 60 weeks old SHR-SP evoked mi-
crovascular pathology such as capillary basement mem-
brane thickening and collagen deposits in the basement
membrane [14,15]. Interestingly, similar cerebrovascular
malformations and related behavioral impairment were re-
ported in normotensive, senescent rats [6–9,35], which sup-
port the theory that chronic hypertension accelerates the
progressive aging-related deterioration of the central ner-
vous system. In addition, both in hypertensive and in aged
animals it was observed that cognitive decline coincided
with changes in neuronal calcium homeostasis. Studies em-
ploying the L-type calcium channel antagonist nimodipine
demonstrated that nimodipine could remarkably moderate
not only signs of neurodegeneration as a consequence of
hypertension or aging, but also the aging-related microvas-
cular abnormalities [6–9,35,36].
Preliminary findings on morphological microvascular
changes in SHR-SP [14,15] raised further questions. First, is
the severity of the pathological changes in capillaries related
to the age of the experimental animals? Second, does cere-
bral microvascular breakdown directly stem from chronic
hypertension or is it caused by a neurogenic derangement of
calcium homeostasis secondary to hypertension? To resolve
these questions, we analyzed the cerebral capillary ultra-
structure of two age groups (40 weeks old and 60 weeks
old) of hypertensive and normotensive rats. Furthermore,
we applied a long-term treatment of two dihydropyridine
type calcium channel blockers nimodipine and nifedipine on
additional experimental groups.
The use of dihydropyridine type calcium channel block-
ers as anti-aging treatment was based on the finding that
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calcium influx through voltage sensitive calcium channels
appeared to be a major contributor to the dysregulation of
neuronal calcium concentration during aging [11,36,44].
The typical, aging-related decline of neural functions (mem-
ory capacity, sensorimotor functions) can stem from the
imbalance of the intracellular calcium homeostasis which
became a target of pharmacological treatment [44]. Nimo-
dipine and nifedipine can protect cellular integrity by bind-
ing to the L-type calcium channels thus blocking the poten-
tially harmful calcium influx to cells. We aimed at making
use of the unique properties of the two drugs that they
penetrate the blood-brain barrier (BBB) [25,32,50] and can
act on neural elements [46]. Nimodipine does not affect
blood pressure, while nifedipine lowers blood pressure in
the here used concentration. Based on the treatments, we
evaluated the ultrastructural lesions of the cerebral capillary
basement membrane in the frontal cortex of 60 weeks old
SHR-SP rats and examined the potentially protective effects
of the drugs on the cerebral microvasculature.
2. Materials and methods
The study was designed to test the effect of aging and the
potentially beneficial effects of two L-type calcium channel
antagonists, nifedipine and nimodipine on the ultrastructure
of cerebral capillaries in male hypertensive rats (SHR-SP,
breeder: Møllegaard, Skønevønd, Denmark). In order to
assess age-related vascular malformations, four groups of
rats were used. These groups were the following: 40-week
old SHR-SP rats (SP-40; n 5 6), 40-week old Wistar Kyoto
rats (WKY-40; n 5 6), 60-week-old WKY rats (WKY-60-
plac; n 5 6) and 60-week-old SHR-SP rats (SP-60-plac;
n 5 8). The WKY animals served as normotensive controls.
The animals were group-housed, lived under a standard 12 h
light-dark cycle and had access to water and food ad libi-
tum.
The behavioral profile of the animals was characterized
by a small open field test, a novelty-induced behavioral
arousal paradigm. The rats were individually placed into a
new cage (24.5 3 24.5 3 30 cm) and were observed for 60
min on week 40 (WKY-40, SP-40) or week 60 (WKY-60,
SP-60). The actual behavioral activity pattern they were
displaying (rearing, grooming, sniffing, walking, immobil-
ity) was registered every 10 s. A behavioral score was
calculated for each kind of explorative activity which re-
flected how often the animal showed that particular behav-
ior in the frame of the 60 min observation time.
The systolic blood pressure values (SBP) of groups
WKY-40 and SP-40 were taken on week 40 before sacri-
fying the animals. The SBP of groups WKY-60-plac and
SP-60-plac were repeatedly measured on every fourth week
between the age of 40 and 60 weeks. The SBP values were
assessed with the tail-cuff method on animals slightly anes-
thetized by ether. Then the rats were anesthetized by an i.p.
overdose of sodium pentobarbital and sacrificed by a trans-
cardiac perfusion of physiological saline containing 1%
heparin followed by a solution of 1% paraformaldehyde,
0.05% glutaraldehyde and 0.2% picric acid in 0.1 M phos-
phate buffer (PB) (pH 7.4). The brains were stored in 1%
paraformaldehyde and 2% glutaraldehyde in 0.1 M PB at
4°C until further processing.
Other groups of WKY and SP animals running parallel
with the above WKY-60-plac and SP-60-plac groups re-
ceived either a nifedipine or a nimodipine treatment for 20
weeks between the age of 40–60 weeks. The compounds
were mixed in the regular rat chow. The daily drug-intake of
the animals was defined as 20–25 mg. The small open field
test of novelty induced exploration was performed together
with the above mentioned four groups. SBP was also mea-
sured on every fourth week and the last value was used for
later correlation analysis. Three groups of SHR-SP rats were
used: 6 animals were fed with nifedipine-containing chow
(SP-60-nife) and 6 animals with nimodipine-containing
food (SP-60-nimo). Each of these groups had their normo-
tensive WKY controls, (WKY-60-nife, n 5 6; WKY-60-
nimo, n 5 6). The food and water intake of the animals, as
well as their body weight was regularly monitored to verify
comparable drug intake of the separate groups. Because of
group housing, the food and water intake of individual
animals was calculated by dividing the absolute amount of
food and water consumed in a cage by the number of
animals in the cage. At the age of 60 weeks, the animals
were anesthetized, perfused, and their brains post-fixed as
described above.
Brain slices were cut at 50 mm with a vibratome, rou-
tinely dehydrated and embedded in glycide ether. Samples
of the frontal cortex at 0.2 mm rostral to Bregma were then
selected and mounted on glycide ether blocks. Non-serial,
ultrathin sections were collected on 200 mesh copper grids
and examined with a Philips 201 and a Philips CM 10
electron microscope.
One hundred capillaries per case were screened through-
out the cortical layers focusing on the microvascular base-
ment membrane (BM) and pericyte pathology as defined in
detail previously [13]. Briefly, the following categories of
capillary abnormalities were distinguished: local basement
membrane thickening (BMT) if the luminal and abluminal
outline of the BM were not running parallel at a given
segment of the membrane, as shown in Fig. 1B. BMT was
additionally characterized by measuring the thickness of the
BM: the width of a healthy BM segment ranged between
50–100 nm while thickening typically varied between 150–
550 nm. Fibrosis referred to excessive collagen type IV
accumulation between two layers of the BM identified by its
periodicity, or collagen invasion to the vascular pericytes
from a split BM (Fig. 1C). When a capillary demonstrated
both BMT and fibrosis, fibrosis overruled BMT and the
capillary was counted only as one with fibrosis. Degenera-
tive pericytes showed abnormal, membranous-appearing in-
clusion bodies or swelling (Fig. 1D). The region investi-
gated did not show signs of cerebrovascular infarcts.
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The density of capillaries was determined as the number
of transversal capillary profiles counted on a standard sur-
face area of 0.2 mm2 spanning all cortical layers. The
diameter of the capillary lumen of 15–24 microvessels of a
standard surface area was also measured. The surface areas
were standardized with the help of the grid mesh.
The data were statistically analyzed by the computer
program SPSS. The quantitative results of capillary ultra-
structure were calculated as percentages of the total number
of vessels investigated, expressed as median values and
evaluated using the Mann-Whitney-U test. SBP was ana-
lyzed by repeated measurement ANOVA, changes in cap-
illary diameter and density by one-way-ANOVA while the
correlation graphs were tested with the Pearson correlation
test.
3. Results
The analysis of the novelty-induced exploration showed
that two of the behavioral parameters, namely rearing and
grooming, significantly differed between groups. Fig. 2A
represents the frequency of rearing behavior. Age-related
decrease of rearing could not be detected when comparing
WKY-40 with WKY-60-plac or SP-40 with SP-60-plac but
clear and significant reduction was seen in SP-40 and SP-
60-plac when compared to their WKY controls. In addition,
nimodipine or nifedipine treatment could increase rearing
behavior to normotensive levels. Grooming activity pre-
sented in Fig. 2B also appeared to be independent of age
under normotensive conditions (WKY), but was consider-
ably reduced in SP-60-plac compared to SP-40 and also to
WKY-60-plac. Thus, the decrease in grooming activity in
old SP could be associated with both age and hypertension.
Nimodipine and nifedipine administration restored the
grooming score to normotensive values in the SP-60 nimo
and SP-60-nife groups.
The SBP values are presented in Fig. 3A & B. The SBP
of the onset SP-40 group was about 60 mmHg higher than
in WKY-40. During the experimental period (20 weeks) the
SBP did not increase in any of the groups. Neither nimo-
dipine, nor nifedipine administration altered the SBP of
aging WKY animals while nifedipine–but not nimodipine–
decreased the SBP in the aging SHR-SP animals already 1
month after the beginning of the treatment.
Fig. 4A & B is showing the food intake of the six 60
weeks old experimental groups while Fig. 4C & D is dem-
onstrating the water intake throughout the calcium antago-
nist-treatment period. It is important to notice that compar-
ing the WKY-60-nimo and WKY-60-nife groups, and the
SP-60-nimo and SP-60-nife groups also with each other, the
animals ate and drank the same amount indicating compa-
rable drug intake. There was no difference in body weight
among the WKY groups (Fig. 4E) but when comparing the
Fig. 1. Schematic drawings demonstrating the transversal profile of an intact cerebral capillary (A), local basement membrane thickening indicated by
arrowheads (B), fibrosis pointed at by arrowheads (C) and pericytic degeneration (D). Abbreviations: e: endothelial cell, en: endothelial nucleus, l: capillary
lumen, p: pericyte, pn: pericytic nucleus, *: basement membrane.
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SP groups, SP-60-nimo rats were significantly heavier than
SP-60-plac animals as analyzed by repeated measurement
ANOVA (F 5 7.156, *P , 0.02). There was no difference
between the SP-60 nimo and SP-60 nife groups (Fig. 4F).
Fig. 5 provides electron microscopic photomicrographs
of microvascular degenerative features assessed in this
study. The age-related changes in capillary integrity were
assessed by comparing the 40 and 60 weeks old groups. Fig.
6 shows that the WKY-60-plac demonstrated an increased
level of BMT, an unchanged degree of fibrosis, and a
significantly higher incidence of pericytic degeneration
when compared to WKY-40. When comparing SP-40 and
SP-60-plac, the difference in capillary basement membrane
pathology appeared to be more pronounced than that seen in
the normotensive WKY rats. Capillaries with BMT oc-
curred three times more frequently in the SP-60-plac than in
the SP-40 and the ratio of fibrosis doubled. An increased
percentage of microvessels with degenerating pericytes was
also found, which was similar to the WKY groups.
Hypertension-related microvascular degeneration could
be investigated by evaluating the differences between the
SHR-SP and WKY animals (Fig. 6A, B & C). The analysis
was completed in both age groups. At the age of 40 weeks,
we found no change in BMT while we saw increased fibro-
sis in the SP-40. The level of pericytic degeneration was
basically not altered. The difference in the percentage of the
individual morphological aberrations between WKY-40 and
SP-40 rats did not reach significance. At 60 weeks of age,
the percentage of both BMT and fibrosis remarkably in-
creased in the SP-60-plac compared to the WKY-60-plac
while the occurrence of degenerative pericytes remained
similar. The graphs seen in Fig. 6D, E & F also characterize
the relationship between microvascular morphological de-
generation and SBP. (Here, not only the placebo experimen-
tal groups but also the treated groups, which are described
in detail bellow, were plotted.) BMT and fibrosis showed a
positive and significant correlation to SBP while the per-
Fig. 2. Novelty-induced exploratory behavioral profile expressed as rearing
frequency (A; *: P , 0.05, **: P , 0.01) and grooming frequency (B; *:
P , 0.05) during 60 min observation. Fig. 3. Systolic blood pressure values measured in the onset groups (A; **:P , 0.01), and the dihydropyridine treated groups (B, *: P , 0.05
WKY-60-plac x SP-60plac, $: P , 0.05 SP-60-plac x SP-60-nimo, 1: P ,
0.05 SP-60-plac x SP-60-nife).
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centage of microvessels with degenerative pericytes ap-
peared to be independent of SBP.
The protective effects of nimodipine and nifedipine on
cortical capillary ultrastructure can be visualized if we com-
pare control and treated animals (Fig. 6A, B & C). In WKY,
the influence of either of the two drugs on BMT or fibrosis
could not be demonstrated. However, nifedipine appeared to
be able to decrease pericytic degeneration in WKY-60-nife
when compared to WKY-60-plac. Thus, it seems that at
physiologically optimal SBP values, nimodipine and nifed-
Fig. 4. Average food- and water intake per animal, and body weight expressed as group mean values during the 20 weeks experimental period. A: food intake
of the WKY animals. B: food intake of the SP animals. C: water intake of the WKY animals. D: water intake of the SP animals. E: body weight of the WKY
groups. F: body weight of the SP groups. Significant differences in body weight based on repeated measurement ANOVA: WKY-60-plac x SP-60-plac: F 5
43.363, **P # 0.000; WKY-60-nife x SP-60-nife: F 5 12.48, *P # 0.005; SP-60-plac x SP-60-nimo: F 5 7.156, *P # 0.02.
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ipine do not alter the ultrastructure of the capillary basement
membrane but nifedipine appears to be a drug that acts on
pericytes. Treatment of the hypertensive animals with the
two drugs yielded to remarkable improvement in capillary
morphology. Nimodipine decreased the incidence of BMT
from 40% (SP-60-plac) to 33% (SP-60-nimo) but the com-
pound had no significant effect either on fibrosis, or on
degenerating pericytes. Nifedipine treatment lead to obser-
Fig. 5. Scanned images of original electron microscopic photographs. A: intact cerebral capillary of a WKY-40 animal. B: BMT of an SP-40 rat. C: BMT
seen in the cortex of an SP-40 rat. D & E: fibrosis as it appears in SP-60-plac animals. F & G: degenerative pericytes in SP-60-plac rats. Abbreviations: e:
endothelial cell, p: pericyte, *: capillary lumen, arrowheads: vascular basement membrane.
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vations similar to that of nimodipine. BMT was signifi-
cantly decreased in SP-60-nife while fibrosis was unaf-
fected. Interestingly, nifedipine improved the condition of
pericytes (SP-60-nife), which finding was not seen after
nimodipine treatment (SP-60-nimo).
Fig. 7C & D show the average capillary diameters cal-
culated for each experimental group. The values ranged
between 9.955 mm (SP-60-nimo) and 10.91 mm (WKY-60-
nife). The microvascular lumen was consistently narrower
in the hypertensive animals than in the normotensive con-
trols, which neither nimodipine nor nifedipine treatment
could noticeably influence. When capillary diameters were
related to SBP of the individual rats, a negative correlation
was established. The density of capillaries considerably
varied but when the three WKY-60 groups and the three
SP-60 groups were combined, an increased number of cap-
illary profiles was detected in the given cortical area in the
hypertensive animals. The correlation of capillary number
Fig. 6. The incidence of capillary basement membrane pathology (A, B) and pericytic degeneration (C) at the age of 60 weeks expressed in median
percentages, and the correlation between systolic blood pressure and microvascular morphology (D, E, F); *: P , 0.05; **: P , 0.01.
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per area unit with SBP did not reveal clear correspondence
with an elevated SBP.
4. Discussion
Here we have assessed ultrastructural damage of rat
cerebrocortical capillaries under chronic hypertensive con-
ditions. The morphological abnormalities described in this
study, namely fibrosis and BMT were also identified in
larger brain vessels in hypertensive humans [42]. Similar
microvascular abnormalities were reported previously in the
cerebral cortex of aging, spontaneously hypertensive rats,
which was, however, restricted to a qualitative description
of capillary pathology [30]. The present study provides
quantitative data, which show that BMT and collagen de-
posits occur considerably more frequently in aging hyper-
tensive rats than in normotensive age-matched controls.
Moreover, such vascular irregularities were not increased in
60 weeks old normotensive rats when compared to a 40
weeks old normotensive group. On the other hand micro-
vascular BMT and fibrosis markedly increased in 60 weeks
old hypertensive animals compared to 40 weeks old
SHR-SP rats. Based on this finding, it may be concluded
that hypertension accelerates capillary damage in the brain.
Our results also indicate that chronic nifedipine or nimo-
dipine treatment can prevent the progression of capillary
wall damage in the rat cerebral cortex. It is known that
dihydropyridines decrease blood pressure by binding to
L-type calcium channels on vascular smooth muscle cells
and inhibit vascular contractility [1,16,28], which, in turn,
gives rise to vasodilatation and reduced vascular resistance
[51]. However, the two drugs have selective effects: varying
doses of nifedipine have been shown to consistently de-
crease blood pressure while nimodipine action on tension
appeared to be concentration dependent [17,18,20,33,46].
At the dose used in the present study, only nifedipine, but
not nimodipine decreased SBP. Although both compounds
improved the condition of cerebral capillaries in a similar
fashion, only the nifedipine-mediated microvascular protec-
Fig. 7. Capillary diameter values (C, *: P , 0.05; **: P , 0.01) and capillary density (D, P , 0.05).
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tion correlated with decreasing SBP while nimodipine ac-
tion was independent of pressure. Thus, the processes un-
derlying the protective effect of the two drugs on cortical
capillaries must be based on more than just lowering blood
pressure.
The location of L-type calcium channels in the micro-
vascular domain, which are the principal targets of nimo-
dipine and nifedipine, may offer further explanations for the
different protective mechanisms of the two drugs. The pri-
mary building blocks of capillaries are the endothelial cells,
which seem not to be endowed with L-type channels, al-
though the occurrence of the L-type channels on the endo-
thelium is a matter of conflicting evidence. Preparations of
isolated bovine vessels or rat pulmonary artery indicated
either the presence [3,37] or the absence [22] of L-type
calcium channels on endothelial cells but a generally pro-
moted concept claims the latter conclusion [1]. Accepting
the lack of L-type channels on the endothelial surface, it is
doubtful that nifedipine or nimodipine can directly act on
the endothelium.
Nifedipine was described to block cellular calcium influx
by binding to L-type calcium channels on peripheral vas-
cular smooth muscle. By doing so, nifedipine attenuates the
contractility of these vascular elements, which leads to de-
creased blood pressure [1,16,28]. Thus, it seems attractive
to reason that vascular protection in our nifedipine treated
animals was achieved by reducing SBP, which assumption
would agree with the correlation found between the percent-
age of intact vessels and SBP. However, the finding that
nimodipine treatment achieved similar microvascular pro-
tection in our paradigm without lowering SBP asks for
another explanation. Since nimodipine and nifedipine were
described to penetrate the brain [25,32,45,46,50] where they
can block calcium influx at neuronal elements [11,44,45],
the mechanisms stimulated by the drugs to preserve capil-
lary integrity may very well lie at CNS level. Astrocytes are
closely related to cerebral microvessels and participate in
the formation and maintenance of the BBB. The astrocytic
endfeet embrace the vascular basement membrane and were
described to be able to regulate the intracerebral vascular
tone and cerebral blood flow indicated by the expression of
serotonergic and cholinergic receptors on the perivascular
endfeet [4,5,12,26,36,41]. Furthermore, astrocytes were
also reported to secrete basement membrane components
[54].
The calcium homeostasis of brain cells including astro-
cytes can be compromised in ischemia. A mild, chronic
ischemic condition in hypertension may emerge from a
reduced cerebral blood flow (CBF) reported in hypertensive
patients as well as hypertensive rats [19,27,38,39]. The
here-used dihydropyridines nimodipine and nifedipine were
shown to increase CBF in SHR rats and rabbits [40,48,49,
53] while clinical trials with nimodipine demonstrated that
the drug improved CBF without having an influence on
systemic blood pressure [17,18,46]. These latter results are
intriguing in the light of our data which show that nimo-
dipine prevented microvascular breakdown without affect-
ing SBP.
Cerebral hypoperfusion, thus also occurring in hyperten-
sion, is known to impose a mild ischemic condition. The
metabolic effects of reduced cerebral blood flow were stud-
ied in animal models of chronic bilateral carotid artery
occlusion. Using this hypoperfusion model, de la Torre and
co-workers reported, for example, a decreased cytochrome
oxidase activity in neuronal mitochondria suggesting a mild
ischemic condition in chronic cerebral hypoperfusion [10],
which implies an increased intracellular calcium concentra-
tion that can impose harmful effects on mitochondrial func-
tion. Furthermore, the elevated calcium concentration is
known to activate detrimental metabolic cascades and is
accompanied by free radical generation [47]. The calcium-
generated synthesis and accumulation of the easily translo-
cating NO and its toxic products [2,34] can attack the
integrity of the BBB: it may cause astrocytic dysfunction
[43] and increased endothelial permeability [24,31,52]. The
here presented microvascular pathology in SHR-SP animals
can be associated with such a chain of events. Nimodipine
treatment can supposedly prevent the intracellular calcium
accumulation, thus moderating free radical production [55]
and consequent cerebral capillary injury.
The possibility that a decreased CBF-induced, mild but
persistent ischemic condition would contribute to the cap-
illary damage seen here could be reflected by changes in
capillary density since cerebral ischemia has been shown to
promote microvascular proliferation. For example, hypoxia
has been demonstrated to lead to the enlargement and pro-
liferation of the microvascular endothelial cells and a con-
sequent increase of cerebral capillary density [21]. Capillary
density was also reported to correlate with the metabolic
rate for glucose [23]. Our data indicate a hypertension-
related decrease in capillary diameter and an increase of
capillary density in the cortical region investigated. These
observations can raise the following assumptions. Consid-
ering that the endothelial cells and pericytes presumably
possess contractile properties [29], a generally narrower
capillary lumen may reflect vasoconstriction typically asso-
ciated with hypertension. The decreased capillary diameter
can be responsible for a lower CBF, which would give rise
to a mild, chronic ischemia represented by the elevated
capillary density. Of course, such hypothesis can only be
fully appreciated if the detection of typical indicators of
ischemia (reduced glucose utilization and oxygen consump-
tion) give support to the vascular observations. Neverthe-
less, a persisting but moderate ischemic condition may well
be causal to the here-described capillary damage, which
could be prevented by dyhidropyridines.
In summary, it has been shown in this study that hyper-
tension can accelerate age-related, ultrastructural capillary
malformations. Microvascular degeneration appears in the
form of vascular basement membrane pathology, such as
BMT and fibrosis. Chronic treatment with dihydropiridine
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drugs, in this case with nimodipine and nifedipine can
prevent the progression of microvascular damage by reduc-
ing the ratio of cerebral capillaries featuring BMT. Thus, in
addition to the well-described beneficial effects of dihy-
dropiridines on neuronal networks, nimodipine and nifedi-
pine have been shown to improve the condition of cerebral
capillaries in chronic hypertension. The underlying mecha-
nism of the process may be related to an increase in CBF,
which leads to an improved neural regulation of cerebro-
vascular function. The precise chain of events, however, is
still to be elucidated.
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